2024 05 v.40 1159-1167
EB病毒感染对儿童机体免疫应答影响的研究进展
基金项目(Foundation):
国家中医药管理局张仲景传承与创新专项（项目号：GZY-KJS-2022-037-2）,题目：仲景热病学术渊源及丁樱国医大师法仲景辨治小儿热病研究;;
河南省特色骨干学科中医学学科建设项目（项目号：STG-ZYX02-202113）,题目：儿童传染性单核细胞增多症的中医治疗优化方案的研究;;
河南中医药大学双一流创建工程项目（项目号：HSRP-DFCTCM-2023-2-16）,题目：儿童传染性单核细胞增多症中医诊疗标准;;
河南省中医药科学研究专项课题（项目号：2018JDZX118）,题目：儿童传染性单核细胞增多症中医文献评价及中西医结合诊疗方案优化研究~~
邮箱(Email):
yanyongbin827@sina.com;
DOI:
10.13242/j.cnki.bingduxuebao.004557
中文作者单位:
河南中医药大学儿科医学院;河南中医药大学第一附属医院儿科医院;
摘要(Abstract):
EB病毒（Epstein-barr virus,EBV）感染在世界范围内常见，人群普遍易感，在我国主要影响学龄期儿童和青少年。多数儿童感染EB病毒后出现传染性单核细胞增多症，但仍有少部分患儿发展成严重的非肿瘤性疾病，如慢性活动性EBV感染和EB病毒相关噬血细胞性组织细胞增生症，预后不良，给患儿家长和社会带来沉重的负担。在原发性EB病毒感染后，机体产生强烈的免疫应答，固有免疫识别病毒后通过分泌细胞因子直接发挥抗EB病毒作用，细胞免疫通过减少病毒载量和消除感染细胞在控制感染中起关键作用。然而，该病毒可以逃逸机体免疫系统，以潜伏感染的形式贮存于记忆性B细胞中，使机体处于终身携带病毒状态，当机体免疫低下或功能障碍时，病毒可重新激活导致一系列严重疾病。目前，EB病毒感染对儿童机体免疫系统的影响尚未完全阐明，儿童EBV相关性疾病的免疫特征尚不明确。研究EB病毒引起的机体免疫应答，开发设计更有效的免疫学疗法和疫苗是亟待解决的紧迫问题。
关键词(KeyWords):
EB病毒感染;;免疫应答;;儿童;;传染性单核细胞增多症;;慢性活动性EB病毒感染;;噬血细胞性组织细胞增生症
| 311 | 0 | 51 |
| 下载次数 | 被引频次 | 阅读次数 |
参考文献
[1] Kerr JR. Epstein-Barr virus(EBV)reactivation and therapeutic inhibitors[J]. J Clin Pathol, 2019, 72(10):651-658. DOI:10. 1136/jclinpath-2019-205822.
[2] Murata T, Sugimoto A, Inagaki T, et al. Molecular basis of Epstein-Barr virus latency establishment and lytic reactivation[J]. Viruses, 2021, 13(12):2344.DOI:10. 3390/v13122344.
[3] Epstein MA, Achong BG, Barr YM. Virus particles in clutured lymphoblasts from Burkitt's lymphoma[J].Lancet, 1964, 1(7335):702-703. DOI:10. 1016/s0140-6736(64)91524-7.
[4] Tangye SG. Genetic susceptibility to EBV infection:insights from inborn errors of immunity[J]. Hum Genet, 2020, 139(6-7):885-901. DOI:10. 1007/s00439-020-02145-3.
[5] Thorley-Lawson DA. Epstein-Barr virus:exploiting the immune system[J]. Nat Rev Immunol, 2001, 1(1):75-82. DOI:10. 1038/35095584.
[6] Busse C, Feederle R, Schn?lzer M, et al. Epstein-Barr viruses that express a CD21 antibody provide evidence that gp350’s functions extend beyond B-cell surface binding[J]. J Virol, 2010, 84(2):1139-1147. DOI:10. 1128/jvi. 01953-09.
[7]左埒莲，朱美娟，都树娟，等. EB病毒侵入宿主细胞机制的研究进展[J].病毒学报，2014, 30(4):476-482.
[8] Tugizov SM, Herrera R, Palefsky JM. Epstein-Barr virus transcytosis through polarized oral epithelial cells[J]. J Virol, 2013, 87(14):8179-8194. DOI:10. 1128/jvi. 00443-13.
[9] Tattevin P, Le Tulzo Y, Minjolle S, et al. Increasing incidence of severe Epstein-Barr virus-related infectious mononucleosis:surveillance study[J]. J Clin Microbiol,2006, 44(5):1873-1874. DOI:10. 1128/jcm. 44. 5. 1873-1874. 2006.
[10]Lee CP, Chen MR. Conquering the nuclear envelope barriers by EBV lytic replication[J]. Viruses, 2021, 13(4):702. DOI:10. 3390/v13040702.
[11]张令歌，孙明姝. EB病毒潜伏期膜蛋白1与自身免疫性疾病关系的研究进展[J].精准医学杂志，2020, 35(1):90-94. DOI:10. 13362/j. jpmed. 202001023.
[12]Shannon-Lowe C, Rickinson A. The global landscape of EBV-associated tumors[J]. Front Oncol, 2019, 9:713. DOI:10. 3389/fonc. 2019. 00713.
[13]Fugl A, Andersen CL. Epstein-Barr virus and its association with disease-a review of relevance to general practice[J]. BMC Fam Pract, 2019, 20(1):62. DOI:10. 1186/s12875-019-0954-3.
[14]王佳兰，张风肖，林玮，等. EB病毒感染在系统性红斑狼疮发病机制中的作用[J].中华临床免疫和变态反应杂志，2022, 16(1):54-59. DOI:10. 3969/j.issn. 1673-8705. 2022. 01. 011.
[15]Huang W, Bai L, Tang H. Epstein-Barr virus infection:the micro and macro worlds[J]. Virol J,2023, 20(1):220. DOI:10. 1186/s12985-023-02187-9.
[16]王红，温文胜. EB病毒对树突状细胞影响的研究进展[J].重庆医学，2015, 44(31):4437-4440.
[17]Severa M, Giacomini E, Gafa V, et al. EBV stimulates TLR-and autophagy-dependent pathways and impairs maturation in plasmacytoid dendritic cells:implications for viral immune escape[J]. Eur J Immunol, 2013, 43(1):147-158. DOI:10. 1002/eji. 201242552.
[18]Quan TE, Roman RM, Rudenga BJ, et al. EpsteinBarr virus promotes interferon-alpha production by plasmacytoid dendritic cells[J]. Arthritis Rheum, 2010,62(6):1693-1701. DOI:10. 1002/art. 27408.
[19]Fiola S, Gosselin D, Takada K, et al. TLR9contributes to the recognition of EBV by primary monocytes and plasmacytoid dendritic cells[J]. J Immunol, 2010, 185(6):3620-3631. DOI:10. 4049/jimmunol. 0903736.
[20]Williams H, McAulay K, MacSween KF, et al. The immune response to primary EBV infection:a role for natural killer cells[J]. Br J Haematol, 2005, 129(2):266-274. DOI:10. 1111/j. 1365-2141. 2005. 05452. x.
[21]Strowig T, Brilot F, Arrey F, et al. Tonsilar NK cells restrict B cell transformation by the Epstein-Barr virus via IFN-gamma[J/OL]. PLoS Pathog, 2008, 4(2):e27. DOI:10. 1371/journal. ppat. 0040027.
[22]Orange JS. Natural killer cell deficiency[J]. J Allergy Clin Immunol, 2013, 132(3):515-525. DOI:10. 1016/j. jaci. 2013. 07. 020.
[23]Duan T, Du Y, Xing C, et al. Toll-like receptor signaling and its role in cell-mediated immunity[J].Front Immunol, 2022, 13:812774. DOI:10. 3389/fimmu. 2022. 812774.
[24]Zhou R, Liu L, Wang Y. Viral proteins recognized by different TLRs[J]. J Med Virol, 2021, 93(11):6116-6123. DOI:10. 1002/jmv. 27265.
[25]Szabo SJ, Sullivan BM, Peng SL, et al. Molecular mechanisms regulating Th1 immune responses[J].Annu Rev Immunol, 2003, 21:713-758. DOI:10. 1146/annurev. immunol. 21. 120601. 140942.
[26]Butcher MJ, Zhu J. Recent advances in understanding the Th1/Th2 effector choice[J]. Fac Rev, 2021, 10:30. DOI:10. 12703/r/10-30.
[27]Yao Y, Kong W, Yang L, et al. Immunity and immune evasion mechanisms of Epstein-Barr virus[J]. Viral Immunol, 2023, 36(5):303-317. DOI:10. 1089/vim. 2022. 0200.
[28]Tomita Y, Avila-Cari?o J, Yamamoto K, et al.Recognition of B-CLL cells experimentally infected with EBV by autologous T lymphocytes[J]. Immunol Lett,1998, 60(2-3):73-79. DOI:10. 1016/s0165-2478(97)00142-9.
[29]中华医学会儿科学分会感染学组，全国儿童EB病毒感染协作组.儿童主要非肿瘤性EB病毒感染相关疾病的诊断和治疗原则建议[J].中华儿科杂志，2016, 54(8):563-568. DOI:10. 3760/cma. j. issn. 0578-1310. 2016. 08. 002.
[30]Liu M, Wang R, Xie Z. T cell-mediated immunity during Epstein–Barr virus infections in children[J].Infect Genet Evol, 2023, 112:105443. DOI:10. 1016/j. meegid. 2023. 105443.
[31]Hislop AD, Taylor GS, Sauce D, et al. Cellular responses to viral infection in humans:lessons from Epstein-Barr virus[J]. Annu Rev Immunol, 2007, 25:587-617.DOI:10. 1146/annurev.immunol. 25. 022106. 141553.
[32]Zuo J, Quinn LL, Tamblyn J, et al. The Epstein-Barr virus-encoded BILF1 protein modulates immune recognition of endogenously processed antigen by targeting major histocompatibility complex class I molecules trafficking on both the exocytic and endocytic pathways[J]. J Virol, 2011, 85(4):1604-1614. DOI:10. 1128/jvi. 01608-10.
[33]Long HM, Chagoury OL, Leese AM, et al. MHC II tetramers visualize human CD4+T cell responses to Epstein-Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response[J]. J Exp Med, 2013, 210(5):933-949. DOI:10. 1084/jem. 20121437.
[34]Zhang Q, Xu M. EBV-induced T-cell responses in EBV-specific and nonspecific cancers[J]. Front Immunol,2023, 14:1250946.DOI:10. 3389/fimmu. 2023. 1250946.
[35]肖梦瑶，辛小娟. EB病毒诱发淋巴增殖性疾病的原因及机制研究进展[J].山东医药，2022, 62(15):98-102.
[36]Odumade OA, Hogquist KA, Balfour HH. Progress and problems in understanding and managing primary Epstein-Barr virus infections[J]. Clin Microbiol Rev,2011, 24(1):193-209. DOI:10. 1128/cmr. 00044-10.
[37]Ohga S, Nomura A, Takada H, et al. Immunological aspects of Epstein–Barr virus infection[J]. Crit Rev Oncol, 2002, 44(3):203-215. DOI:10. 1016/S1040-8428(02)00112-9.
[38]Shafiee A, Shamsi S, Kohandel Gargari O, et al. EBV associated T-and NK-cell lymphoproliferative diseases:a comprehensive overview of clinical manifestations and novel therapeutic insights[J]. Rev Med Virol, 2022, 32(4):e2328. DOI:10. 1002/rmv. 2328.
[39]Quinn LL, Zuo J, Abbott RJ, et al. Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+T cell recognition across all three phases of the lytic cycle[J/OL]. PLoS Pathog,2014, 10(8):e1004322. DOI:10. 1371/journal.ppat. 1004322.
[40]Rowe M, Glaunsinger B, van Leeuwen D, et al. Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion[J]. Proc Natl Acad Sci USA, 2007, 104(9):3366-3371. DOI:10. 1073/pnas. 0611128104.
[41]Bentz GL, Liu R, Hahn AM, et al. Epstein–Barr virus BRLF1 inhibits transcription of IRF3 and IRF7and suppresses induction of interferon-Β[J]. Virology,2010, 402(1):121-128. DOI:10. 1016/j.virol. 2010. 03. 014.
[42]Apcher S, Komarova A, Daskalogianni C, et al.mRNA translation regulation by the Gly-Ala repeat of Epstein-Barr virus nuclear antigen 1[J]. J Virol, 2009,83(3):1289-1298. DOI:10. 1128/jvi. 01369-08.
[43]Valentine R, Dawson CW, Hu C, et al. Epstein-Barr virus-encoded EBNA1 inhibits the canonical NF-kappaB pathway in carcinoma cells by inhibiting IKK phosphorylation[J]. Mol Cancer, 2010, 9:1. DOI:10. 1186/1476-4598-9-1.
[44]Ho HH, Ivashkiv LB. Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation[J]. Biol Chem,2006, 281(20):14111-14118. DOI:10. 1074/jbc.M511797200.
[45]Fathallah I, Parroche P, Gruffat H, et al. EBV latent membrane protein 1 is a negative regulator of TLR9[J].J Immunol, 2010, 185(11):6439-6447. DOI:10. 4049/jimmunol. 0903459.
[46]Zhao Y, Xu D, Jiang Y, et al. Dual functions of interferon regulatory factors 7C in Epstein-Barr virusmediated transformation of human B lymphocytes[J/OL]. PLoS One, 2010, 5(3):e9459. DOI:10. 1371/journal. pone. 0009459.
[47]Qiu J, Smith P, Leahy L, et al. The Epstein-Barr virus encoded BART miRNAs potentiate tumor growth in vivo[J/OL]. PLoS Pathog, 2015, 11(1):e1004561.DOI:10. 1371/journal. ppat. 1004561.
[48]Trapani JA, Sutton VR. Granzyme B:pro-apoptotic,antiviral and antitumor functions[J]. Curr Opin Immunol, 2003, 15(5):533-543. DOI:10. 1016/S0952-7915(03)00107-9.
[49]Palendira U, Rickinson AB.Primary immunodeficiencies and the control of Epstein-Barr virus infection[J]. Ann N Y Acad Sci, 2015, 1356:22-44.DOI:10. 1111/nyas. 12937.
[50]Naughton P, Healy M, Enright F, et al. Infectious Mononucleosis:diagnosis and clinical interpretation[J].Br J Biomed Sci, 2021, 78(3):107-116. DOI:10. 1080/09674845. 2021. 1903683.
[51]Wang Y, Luo Y, Tang G, et al. HLA-DR expression level in CD8+T cells correlates with the severity of children with acute infectious mononucleosis[J]. Front Immunol, 2021, 12:753290. DOI:10. 3389/fimmu. 2021. 753290.
[52]Taylor GS, Long HM, Brooks JM, et al. The immunology of Epstein-Barr virus-induced disease[J].Annu Rev Immunol, 2015, 33:787-821. DOI:10. 1146/annurev-immunol-032414-112326.
[53]陈若红，冯业成，黄慧敏，等. EBV感染患儿临床特征及血清免疫因子水平[J].中华医院感染学杂志，2021, 31(3):463-467. DOI:10. 11816/cn. ni. 2021-201346.
[54]胡湘萍，张敬芳，段永彬. Th1/Th2细胞失衡在EB病毒感染患儿发病中的作用研究[J].中国卫生检验杂志，2023, 33(18):2264-2266. DOI:10. 3969/j.issn. 1673-4130. 2022. 03. 014.
[55]张垚，汤永民.儿童噬血细胞综合征的研究进展[J].中国小儿血液与肿瘤杂志，2020, 25(2):112-117.DOI:10. 3969/j. issn. 1673-5323. 2020. 02. 014.
[56]Wang H, Xiong L, Tang W, et al. A systematic review of malignancy-associated hemophagocytic lymphohistiocytosis that needs more attentions[J].Oncotarget, 2017, 8(35):59977-59985. DOI:10. 18632/oncotarget. 19230.
[57]Rubin TS, Zhang K, Gifford C, et al. Perforin and CD107a testing is superior to NK cell function testing for screening patients for genetic HLH[J]. Blood, 2017,129(22):2993-2999. DOI:10. 1182/blood-2016-12-753830.
[58]Zimmer M, Gill I, Anusim N, et al. Epstein-Barr virus induced haemophagocytic lymphohistiocytosis[J]. BMJ Case Rep, 2021, 14(5):e241348. DOI:10. 1136/bcr-2020-241348.
[59]Bollard CM, Cohen JI. How I treat T-cell chronic active Epstein-Barr virus disease[J]. Blood, 2018, 131(26):2899-2905. DOI:10. 1182/blood-2018-03-785931.
[60]Paik JH, Choe JY, Kim H, et al. Clinicopathological categorization of Epstein–Barr virus-positive T/NKcell lymphoproliferative disease:an analysis of 42 cases with an emphasis on prognostic implications[J]. Leuk Lymphoma, 2017, 58(1):53-63. DOI:10. 1080/10428194. 2016. 1179297.
[61]吴小容，王建林，段子渊.慢性活动型EB病毒感染的致病机理研究进展[J].生物化学与生物物理进展，2016, 43(10):980-989. DOI:10. 16476/j.pibb. 2016. 0255.
[62]秦强，谢正德.慢性活动性EBV感染的诊疗进展[J].传染病信息，2019, 32(2):175-180. DOI:10. 3969/j.issn. 1007-8134. 2019. 02. 020.
[63]安晓红，曾毅. EB病毒疫苗研究进展[J].中国疫苗和免疫，2018, 24(3):360-364.
[64]Zhong L, Krummenacher C, Zhang W, et al. Urgency and necessity of Epstein-Barr virus prophylactic vaccines[J]. NPJ Vaccines, 2022, 7:159. DOI:10. 1038/s41541-022-00587-6.
[2] Murata T, Sugimoto A, Inagaki T, et al. Molecular basis of Epstein-Barr virus latency establishment and lytic reactivation[J]. Viruses, 2021, 13(12):2344.DOI:10. 3390/v13122344.
[3] Epstein MA, Achong BG, Barr YM. Virus particles in clutured lymphoblasts from Burkitt's lymphoma[J].Lancet, 1964, 1(7335):702-703. DOI:10. 1016/s0140-6736(64)91524-7.
[4] Tangye SG. Genetic susceptibility to EBV infection:insights from inborn errors of immunity[J]. Hum Genet, 2020, 139(6-7):885-901. DOI:10. 1007/s00439-020-02145-3.
[5] Thorley-Lawson DA. Epstein-Barr virus:exploiting the immune system[J]. Nat Rev Immunol, 2001, 1(1):75-82. DOI:10. 1038/35095584.
[6] Busse C, Feederle R, Schn?lzer M, et al. Epstein-Barr viruses that express a CD21 antibody provide evidence that gp350’s functions extend beyond B-cell surface binding[J]. J Virol, 2010, 84(2):1139-1147. DOI:10. 1128/jvi. 01953-09.
[7]左埒莲，朱美娟，都树娟，等. EB病毒侵入宿主细胞机制的研究进展[J].病毒学报，2014, 30(4):476-482.
[8] Tugizov SM, Herrera R, Palefsky JM. Epstein-Barr virus transcytosis through polarized oral epithelial cells[J]. J Virol, 2013, 87(14):8179-8194. DOI:10. 1128/jvi. 00443-13.
[9] Tattevin P, Le Tulzo Y, Minjolle S, et al. Increasing incidence of severe Epstein-Barr virus-related infectious mononucleosis:surveillance study[J]. J Clin Microbiol,2006, 44(5):1873-1874. DOI:10. 1128/jcm. 44. 5. 1873-1874. 2006.
[10]Lee CP, Chen MR. Conquering the nuclear envelope barriers by EBV lytic replication[J]. Viruses, 2021, 13(4):702. DOI:10. 3390/v13040702.
[11]张令歌，孙明姝. EB病毒潜伏期膜蛋白1与自身免疫性疾病关系的研究进展[J].精准医学杂志，2020, 35(1):90-94. DOI:10. 13362/j. jpmed. 202001023.
[12]Shannon-Lowe C, Rickinson A. The global landscape of EBV-associated tumors[J]. Front Oncol, 2019, 9:713. DOI:10. 3389/fonc. 2019. 00713.
[13]Fugl A, Andersen CL. Epstein-Barr virus and its association with disease-a review of relevance to general practice[J]. BMC Fam Pract, 2019, 20(1):62. DOI:10. 1186/s12875-019-0954-3.
[14]王佳兰，张风肖，林玮，等. EB病毒感染在系统性红斑狼疮发病机制中的作用[J].中华临床免疫和变态反应杂志，2022, 16(1):54-59. DOI:10. 3969/j.issn. 1673-8705. 2022. 01. 011.
[15]Huang W, Bai L, Tang H. Epstein-Barr virus infection:the micro and macro worlds[J]. Virol J,2023, 20(1):220. DOI:10. 1186/s12985-023-02187-9.
[16]王红，温文胜. EB病毒对树突状细胞影响的研究进展[J].重庆医学，2015, 44(31):4437-4440.
[17]Severa M, Giacomini E, Gafa V, et al. EBV stimulates TLR-and autophagy-dependent pathways and impairs maturation in plasmacytoid dendritic cells:implications for viral immune escape[J]. Eur J Immunol, 2013, 43(1):147-158. DOI:10. 1002/eji. 201242552.
[18]Quan TE, Roman RM, Rudenga BJ, et al. EpsteinBarr virus promotes interferon-alpha production by plasmacytoid dendritic cells[J]. Arthritis Rheum, 2010,62(6):1693-1701. DOI:10. 1002/art. 27408.
[19]Fiola S, Gosselin D, Takada K, et al. TLR9contributes to the recognition of EBV by primary monocytes and plasmacytoid dendritic cells[J]. J Immunol, 2010, 185(6):3620-3631. DOI:10. 4049/jimmunol. 0903736.
[20]Williams H, McAulay K, MacSween KF, et al. The immune response to primary EBV infection:a role for natural killer cells[J]. Br J Haematol, 2005, 129(2):266-274. DOI:10. 1111/j. 1365-2141. 2005. 05452. x.
[21]Strowig T, Brilot F, Arrey F, et al. Tonsilar NK cells restrict B cell transformation by the Epstein-Barr virus via IFN-gamma[J/OL]. PLoS Pathog, 2008, 4(2):e27. DOI:10. 1371/journal. ppat. 0040027.
[22]Orange JS. Natural killer cell deficiency[J]. J Allergy Clin Immunol, 2013, 132(3):515-525. DOI:10. 1016/j. jaci. 2013. 07. 020.
[23]Duan T, Du Y, Xing C, et al. Toll-like receptor signaling and its role in cell-mediated immunity[J].Front Immunol, 2022, 13:812774. DOI:10. 3389/fimmu. 2022. 812774.
[24]Zhou R, Liu L, Wang Y. Viral proteins recognized by different TLRs[J]. J Med Virol, 2021, 93(11):6116-6123. DOI:10. 1002/jmv. 27265.
[25]Szabo SJ, Sullivan BM, Peng SL, et al. Molecular mechanisms regulating Th1 immune responses[J].Annu Rev Immunol, 2003, 21:713-758. DOI:10. 1146/annurev. immunol. 21. 120601. 140942.
[26]Butcher MJ, Zhu J. Recent advances in understanding the Th1/Th2 effector choice[J]. Fac Rev, 2021, 10:30. DOI:10. 12703/r/10-30.
[27]Yao Y, Kong W, Yang L, et al. Immunity and immune evasion mechanisms of Epstein-Barr virus[J]. Viral Immunol, 2023, 36(5):303-317. DOI:10. 1089/vim. 2022. 0200.
[28]Tomita Y, Avila-Cari?o J, Yamamoto K, et al.Recognition of B-CLL cells experimentally infected with EBV by autologous T lymphocytes[J]. Immunol Lett,1998, 60(2-3):73-79. DOI:10. 1016/s0165-2478(97)00142-9.
[29]中华医学会儿科学分会感染学组，全国儿童EB病毒感染协作组.儿童主要非肿瘤性EB病毒感染相关疾病的诊断和治疗原则建议[J].中华儿科杂志，2016, 54(8):563-568. DOI:10. 3760/cma. j. issn. 0578-1310. 2016. 08. 002.
[30]Liu M, Wang R, Xie Z. T cell-mediated immunity during Epstein–Barr virus infections in children[J].Infect Genet Evol, 2023, 112:105443. DOI:10. 1016/j. meegid. 2023. 105443.
[31]Hislop AD, Taylor GS, Sauce D, et al. Cellular responses to viral infection in humans:lessons from Epstein-Barr virus[J]. Annu Rev Immunol, 2007, 25:587-617.DOI:10. 1146/annurev.immunol. 25. 022106. 141553.
[32]Zuo J, Quinn LL, Tamblyn J, et al. The Epstein-Barr virus-encoded BILF1 protein modulates immune recognition of endogenously processed antigen by targeting major histocompatibility complex class I molecules trafficking on both the exocytic and endocytic pathways[J]. J Virol, 2011, 85(4):1604-1614. DOI:10. 1128/jvi. 01608-10.
[33]Long HM, Chagoury OL, Leese AM, et al. MHC II tetramers visualize human CD4+T cell responses to Epstein-Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response[J]. J Exp Med, 2013, 210(5):933-949. DOI:10. 1084/jem. 20121437.
[34]Zhang Q, Xu M. EBV-induced T-cell responses in EBV-specific and nonspecific cancers[J]. Front Immunol,2023, 14:1250946.DOI:10. 3389/fimmu. 2023. 1250946.
[35]肖梦瑶，辛小娟. EB病毒诱发淋巴增殖性疾病的原因及机制研究进展[J].山东医药，2022, 62(15):98-102.
[36]Odumade OA, Hogquist KA, Balfour HH. Progress and problems in understanding and managing primary Epstein-Barr virus infections[J]. Clin Microbiol Rev,2011, 24(1):193-209. DOI:10. 1128/cmr. 00044-10.
[37]Ohga S, Nomura A, Takada H, et al. Immunological aspects of Epstein–Barr virus infection[J]. Crit Rev Oncol, 2002, 44(3):203-215. DOI:10. 1016/S1040-8428(02)00112-9.
[38]Shafiee A, Shamsi S, Kohandel Gargari O, et al. EBV associated T-and NK-cell lymphoproliferative diseases:a comprehensive overview of clinical manifestations and novel therapeutic insights[J]. Rev Med Virol, 2022, 32(4):e2328. DOI:10. 1002/rmv. 2328.
[39]Quinn LL, Zuo J, Abbott RJ, et al. Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+T cell recognition across all three phases of the lytic cycle[J/OL]. PLoS Pathog,2014, 10(8):e1004322. DOI:10. 1371/journal.ppat. 1004322.
[40]Rowe M, Glaunsinger B, van Leeuwen D, et al. Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion[J]. Proc Natl Acad Sci USA, 2007, 104(9):3366-3371. DOI:10. 1073/pnas. 0611128104.
[41]Bentz GL, Liu R, Hahn AM, et al. Epstein–Barr virus BRLF1 inhibits transcription of IRF3 and IRF7and suppresses induction of interferon-Β[J]. Virology,2010, 402(1):121-128. DOI:10. 1016/j.virol. 2010. 03. 014.
[42]Apcher S, Komarova A, Daskalogianni C, et al.mRNA translation regulation by the Gly-Ala repeat of Epstein-Barr virus nuclear antigen 1[J]. J Virol, 2009,83(3):1289-1298. DOI:10. 1128/jvi. 01369-08.
[43]Valentine R, Dawson CW, Hu C, et al. Epstein-Barr virus-encoded EBNA1 inhibits the canonical NF-kappaB pathway in carcinoma cells by inhibiting IKK phosphorylation[J]. Mol Cancer, 2010, 9:1. DOI:10. 1186/1476-4598-9-1.
[44]Ho HH, Ivashkiv LB. Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation[J]. Biol Chem,2006, 281(20):14111-14118. DOI:10. 1074/jbc.M511797200.
[45]Fathallah I, Parroche P, Gruffat H, et al. EBV latent membrane protein 1 is a negative regulator of TLR9[J].J Immunol, 2010, 185(11):6439-6447. DOI:10. 4049/jimmunol. 0903459.
[46]Zhao Y, Xu D, Jiang Y, et al. Dual functions of interferon regulatory factors 7C in Epstein-Barr virusmediated transformation of human B lymphocytes[J/OL]. PLoS One, 2010, 5(3):e9459. DOI:10. 1371/journal. pone. 0009459.
[47]Qiu J, Smith P, Leahy L, et al. The Epstein-Barr virus encoded BART miRNAs potentiate tumor growth in vivo[J/OL]. PLoS Pathog, 2015, 11(1):e1004561.DOI:10. 1371/journal. ppat. 1004561.
[48]Trapani JA, Sutton VR. Granzyme B:pro-apoptotic,antiviral and antitumor functions[J]. Curr Opin Immunol, 2003, 15(5):533-543. DOI:10. 1016/S0952-7915(03)00107-9.
[49]Palendira U, Rickinson AB.Primary immunodeficiencies and the control of Epstein-Barr virus infection[J]. Ann N Y Acad Sci, 2015, 1356:22-44.DOI:10. 1111/nyas. 12937.
[50]Naughton P, Healy M, Enright F, et al. Infectious Mononucleosis:diagnosis and clinical interpretation[J].Br J Biomed Sci, 2021, 78(3):107-116. DOI:10. 1080/09674845. 2021. 1903683.
[51]Wang Y, Luo Y, Tang G, et al. HLA-DR expression level in CD8+T cells correlates with the severity of children with acute infectious mononucleosis[J]. Front Immunol, 2021, 12:753290. DOI:10. 3389/fimmu. 2021. 753290.
[52]Taylor GS, Long HM, Brooks JM, et al. The immunology of Epstein-Barr virus-induced disease[J].Annu Rev Immunol, 2015, 33:787-821. DOI:10. 1146/annurev-immunol-032414-112326.
[53]陈若红，冯业成，黄慧敏，等. EBV感染患儿临床特征及血清免疫因子水平[J].中华医院感染学杂志，2021, 31(3):463-467. DOI:10. 11816/cn. ni. 2021-201346.
[54]胡湘萍，张敬芳，段永彬. Th1/Th2细胞失衡在EB病毒感染患儿发病中的作用研究[J].中国卫生检验杂志，2023, 33(18):2264-2266. DOI:10. 3969/j.issn. 1673-4130. 2022. 03. 014.
[55]张垚，汤永民.儿童噬血细胞综合征的研究进展[J].中国小儿血液与肿瘤杂志，2020, 25(2):112-117.DOI:10. 3969/j. issn. 1673-5323. 2020. 02. 014.
[56]Wang H, Xiong L, Tang W, et al. A systematic review of malignancy-associated hemophagocytic lymphohistiocytosis that needs more attentions[J].Oncotarget, 2017, 8(35):59977-59985. DOI:10. 18632/oncotarget. 19230.
[57]Rubin TS, Zhang K, Gifford C, et al. Perforin and CD107a testing is superior to NK cell function testing for screening patients for genetic HLH[J]. Blood, 2017,129(22):2993-2999. DOI:10. 1182/blood-2016-12-753830.
[58]Zimmer M, Gill I, Anusim N, et al. Epstein-Barr virus induced haemophagocytic lymphohistiocytosis[J]. BMJ Case Rep, 2021, 14(5):e241348. DOI:10. 1136/bcr-2020-241348.
[59]Bollard CM, Cohen JI. How I treat T-cell chronic active Epstein-Barr virus disease[J]. Blood, 2018, 131(26):2899-2905. DOI:10. 1182/blood-2018-03-785931.
[60]Paik JH, Choe JY, Kim H, et al. Clinicopathological categorization of Epstein–Barr virus-positive T/NKcell lymphoproliferative disease:an analysis of 42 cases with an emphasis on prognostic implications[J]. Leuk Lymphoma, 2017, 58(1):53-63. DOI:10. 1080/10428194. 2016. 1179297.
[61]吴小容，王建林，段子渊.慢性活动型EB病毒感染的致病机理研究进展[J].生物化学与生物物理进展，2016, 43(10):980-989. DOI:10. 16476/j.pibb. 2016. 0255.
[62]秦强，谢正德.慢性活动性EBV感染的诊疗进展[J].传染病信息，2019, 32(2):175-180. DOI:10. 3969/j.issn. 1007-8134. 2019. 02. 020.
[63]安晓红，曾毅. EB病毒疫苗研究进展[J].中国疫苗和免疫，2018, 24(3):360-364.
[64]Zhong L, Krummenacher C, Zhang W, et al. Urgency and necessity of Epstein-Barr virus prophylactic vaccines[J]. NPJ Vaccines, 2022, 7:159. DOI:10. 1038/s41541-022-00587-6.
基本信息:
DOI：10.13242/j.cnki.bingduxuebao.004557
中图分类号:R725.1
引用信息:
[1]张宇婧,郭旭冉,郑海涛等.EB病毒感染对儿童机体免疫应答影响的研究进展[J].病毒学报,2024,40(05):1159-1167.DOI:10.13242/j.cnki.bingduxuebao.004557.
基金信息:
国家中医药管理局张仲景传承与创新专项（项目号：GZY-KJS-2022-037-2）,题目：仲景热病学术渊源及丁樱国医大师法仲景辨治小儿热病研究;; 河南省特色骨干学科中医学学科建设项目（项目号：STG-ZYX02-202113）,题目：儿童传染性单核细胞增多症的中医治疗优化方案的研究;; 河南中医药大学双一流创建工程项目（项目号：HSRP-DFCTCM-2023-2-16）,题目：儿童传染性单核细胞增多症中医诊疗标准;; 河南省中医药科学研究专项课题（项目号：2018JDZX118）,题目：儿童传染性单核细胞增多症中医文献评价及中西医结合诊疗方案优化研究~~
暂无数据